Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

ABSTRACT Background Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods Estimated RSV hospitalisations in < 1‐year‐olds during weeks 40, 2023...

Full description

Saved in:

Bibliographic Details
Published in:	Influenza and other respiratory viruses Vol. 18; no. 5; pp. e13294 - n/a
Main Authors:	Mazagatos, Clara, Mendioroz, Jacobo, Rumayor, Mercedes Belén, Gallardo García, Virtudes, Álvarez Río, Virginia, Cebollada Gracia, Ana Delia, Batalla Rebollo, Noa, Barranco Boada, María Isabel, Pérez‐Martínez, Olaia, Lameiras Azevedo, Ana Sofía, López González‐Coviella, Nieves, Castrillejo, Daniel, Fernández Ibáñez, Ana, Giménez Duran, Jaume, Ramírez Córcoles, Cristina, Ramos Marín, Violeta, Larrauri, Amparo, Monge, Susana, Basile, Luca, García Comas, Luis, Lorusso, Nicola, Pacheco Martínez, María del Carmen, Rodríguez Martí, Cristina, Linares Dópido, Juan Antonio, Sánchez‐Migallon Naranjo, Alonso, Otero‐Barrós, María Teresa, Lopez Torrijos, Miriam, Rivas Wagner, Eva, Hermoso Castro, Luisa F., Huerta Huerta, Marta, Reina Prieto, Jorge, Gómez Juárez, Ana, Ruiz Nuñez, Aranzazu, González Carril, Fernando, Imaz Goienetxea, Liher, Ibáñez Pérez, Ana Carmen, Berradre Saenz, Belén, Puma Olguin, Tania, Pérez Gimeno, Gloria, Galindo Carretero, Silvia, Vega Piris, Lorena, Lozano, Marcos
Format:	Journal Article
Language:	English
Published:	England John Wiley & Sons, Inc 01-05-2024 John Wiley and Sons Inc
Subjects:	Age groups Antibodies Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - therapeutic use Babies burden Child care Childrens health Disease prevention Epidemiology Female Health care policy Health surveillance Hospitalization Hospitalization - statistics & numerical data Humans impact Incidence Infant Infant, Newborn Infections Male Newborn babies Pandemics Pediatrics Public health respiratory infections respiratory syncitial virus Respiratory syncytial virus Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus, Human Respiratory tract infection SARI Seasons Sentinel Surveillance Short Communication Short Communications Spain - epidemiology surveillance Surveillance systems Spain respiratory syncitial virus SARI surveillance respiratory infections impact burden
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	ABSTRACT Background Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods Estimated RSV hospitalisations in < 1‐year‐olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction.
Bibliography:	Funding During the implementation of sentinel SARI surveillance in Spain, some Autonomous Communities received funding from ECDC (Establishing Severe Acute Respiratory Infections [SARI] surveillance and performing hospital‐based COVID‐19 transmission studies, ECDC.11236.2021). Researchers at the National Centre of Epidemiology (Institute of Heath Carlos III) received funding from ECDC through the project ‘ECDC Hospital network for Vaccine Effectiveness, Burden and Impact Studies and for Surveillance of Severe Acute Respiratory Infections’ Framework Contract no. ECDC/2021/016, within the ‘Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID‐19 and Influenza’ platform. For a complete list of the SARI Sentinel Surveillance RSV Study Group, see the Acknowledgments section. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Funding: During the implementation of sentinel SARI surveillance in Spain, some Autonomous Communities received funding from ECDC (Establishing Severe Acute Respiratory Infections [SARI] surveillance and performing hospital‐based COVID‐19 transmission studies, ECDC.11236.2021). Researchers at the National Centre of Epidemiology (Institute of Heath Carlos III) received funding from ECDC through the project ‘ECDC Hospital network for Vaccine Effectiveness, Burden and Impact Studies and for Surveillance of Severe Acute Respiratory Infections’ Framework Contract no. ECDC/2021/016, within the ‘Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID‐19 and Influenza’ platform.
ISSN:	1750-2640 1750-2659 1750-2659
DOI:	10.1111/irv.13294